Avoiding biases when estimating effects of COVID-19 vaccination during immune checkpoint inhibitor therapy

Authors: Elise Dumas[1], Paul Gougis[2,3,4], Lorenzo Gasparollo[1], Jean-Philippe Spano[3], Mats Julius Stensrud[1]

Affiliations:

[1]Institute of Mathematics, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
[2]Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité F-75005 Paris, France.
[3]Department of Medical Oncology, Pitié-Salpêtrière hospital, Sorbonne Université, Institut Universitaire du Cancer, Paris, France.
[4]Clinical Investigation Center (CIC-1901) INSERM, Department of Pharmacology, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.

Corresponding author:

Dr Elise DUMAS
Primary email : elise.dumas@epfl.ch
Secondary email : elise.dumas28@gmail.com
EPFL SB MATH BIOSTAT (Bâtiment MA), Station 8 CH-1015 Lausanne, Switzerland
+41772874252
ORCID : https://orcid.org/0000-0002-7877-719X

Emails of other authors:

Paul Gougis: paul.gougis@gmail.com
Lorenzo Gasparollo: lorenzo.gasparollo@epfl.ch
Jean-Philippe Spano: jean-philippe.spano@aphp.fr
Mats Julius Stensrud: mats.stensrud@epfl.ch

Abstract:

SARS-CoV-2 mRNA vaccination (COVID-19 vaccination) within 100 days of immune checkpoint inhibitor (ICI) treatment was reported to improve survival and prevent disease progression in patients with non-small cell lung cancer (NSCLC) and metastatic melanoma (Grippin *et al.*, Nature, 2025). However, the clinical evidence, derived from real-world observational data, suffers from methodological limitations. Specifically, the vaccinated and unvaccinated groups differed in subtle ways due to the timing of vaccination, the beginning of follow-up, and the definition of eligibility. These key limitations can be overcome by carefully conducting a target trial emulation analysis. Using the original data from Grippin *et al.*, we emulated a target trial to estimate the causal effect of COVID-19 vaccination within 100 days of ICI initiation on overall survival and progression-free survival in patients with NSCLC and metastatic melanoma. In contrast to the original analysis, we found no evidence that COVID-19 vaccination improves survival outcomes in these populations.

Standfirst:

Claims that SARS-CoV-2 mRNA vaccination within 100 days of starting immune checkpoint inhibitor therapy improves survival in non-small cell lung cancer and metastatic melanoma led us to reanalyze the original dataset by emulating a target trial that aligns time zero, harmonizes eligibility across treatment arms, and addresses immortal-time and selection bias, and we then found no evidence of benefit in either cancer population.

Summary points:

-Claims based on observational data suggest that SARS-CoV-2 mRNA vaccination within 100 days of starting ICI improves survival in NSCLC and melanoma.

-The original analysis misaligned time zero and eligibility across groups, introducing immortal-time and selection biases.

-Target-trial emulation addresses these issues by explicitly aligning eligibility, treatment assignment, and start of follow-up.

-Reanalyzing the same dataset with an explicit target trial emulation shows no evidence of improved overall or progression-free survival.

Introduction

A recent study suggests that SARS-CoV-2 mRNA vaccines (COVID-19 vaccines) sensitize tumours to immune checkpoint blockade and increase the effectiveness of immune checkpoint inhibitors (ICIs).[1] The clinical evidence comes from an observational analysis, in which vaccinated patients with stage III/IV non-small cell lung cancer (NSCLC) and stage IV melanoma appeared to have lower risks of death. Specifically, survival improvements of 24.9 percentage-points were observed after 3 years in the vaccinated group compared to the unvaccinated group (55.7% versus 30.8%; adjusted hazard ratio (HR) 0.51, 95% confidence interval (CI) 0.37–0.71) in patients with NSCLC, and of 23.5 percentage-points (44.1% versus 67.6%; HR 0.37, 95% CI 0.18–0.74) in patients with stage IV melanoma. Furthermore, COVID-19 vaccination appeared to increase progression-free survival (PFS) in the stage IV melanoma cohort.

However, the vaccinated and unvaccinated groups differed in subtle ways due to the timing of vaccination, the beginning of follow-up, and the definition of eligibility. The vaccine group was defined using information occurring after the start of follow-up. The unvaccinated group included individuals from earlier years, when vaccines were not available. Time zero was defined differently in the two groups: the unvaccinated individuals were followed from their first ICI treatment, and the vaccinated individuals were followed from their ICI treatment preceding vaccination. These misalignments can lead to substantial bias and compromise the causal interpretations of the results.[2] However, this type of bias can be mitigated by carefully emulating a target trial within a formal framework of causal inference. Indeed, target trial emulation is designed to avoid such biases, and requires an explicit specification of the start of follow-up, treatment assignment, and time of eligibility.[3] A target trial emulation is based on describing a hypothetical randomized trial that would answer the research question of interest, and then on reproducing its key components as closely as possible using the available observational data.[4]

Using data from Grippin *et al.,*[1] we emulated a target trial on COVID-19 vaccination to reduce biases from time zero misalignment.

Emulation of a target trial for the effect of COVID-19 mRNA vaccines on cancer outcomes

Specification of the target trial protocol

In the hypothetical trial, we would include patients with either stage III/IV NSCLC or stage IV melanoma who initiated ICI treatment after the COVID-19 vaccines became available. Patients would be randomly assigned to one of the two interventions: (i) get a COVID-19 vaccine within 100 days of the first ICI or (ii) do not get a COVID-19 vaccine within 100 days of the first ICI. Patients would be followed from the first date of ICI up to September 2024. The primary outcomes would be overall survival (OS) at 36 months for NSCLC and OS and progression-free survival (PFS) at 36 months for stage IV melanoma. The full protocol of the hypothetical target trial is detailed in Table 1.

Emulation of the hypothetical target trial

We emulated the hypothetical target trial using the data presented by Grippin et *al.*, which were available online for NSCLC patients and stage IV melanoma patients (dataset access: 11/01/2025). Details on the target trial emulation are given in Table 1. We used a clone-censor-weight approach.[5] Inverse probability of censoring weights were based on baseline confounders, including socio-demographic factors and comorbid conditions. The code is available online (https://github.com/elisedms/target-trial-emulation-covid-vaccine-ICI).

Results

Out of 884 patients in the original NSCLC cohort, we included 277 patients in the target trial emulation, among whom 140 (50.5%) received a COVID-19 vaccine within 100 days of first ICI (Figure 1A). Similarly, out of 210 patients in the original stage IV melanoma cohort, we included 134 patients, among whom 43 (32.1%) received a COVID-19 vaccine within 100 days of first ICI (Figure 1B). For patients with NSCLC, 3-year OS was 52.7% (95% CI 42.0–63.0) in the vaccinated arm and 46.3% (95% CI 34.9–56.5) in the unvaccinated arm (difference: 6.4 percentage-points, 95% CI -8.2–21.2) (Figure 2A). For patients with stage IV melanoma, 3-year OS was 65.7% (95% CI 47.9–80.8) in the vaccinated arm and 49.2% (95% CI 34.2–64.1) in the unvaccinated arm (difference: 16.5 percentage-points, 95% CI -5.6–36.8) (Figure 2B).

PFS at 3 years for patients with stage IV melanoma was 34.7% (95% CI 21.4–48.5) in the vaccinated arm compared with 29.5% (95% CI 15.3–43.9) in the unvaccinated arm (difference: 5.2 percentage-points, 95% CI -14.5–25.4) (Figure 2C).

Misalignment of study times matters

We found no evidence that COVID-19 vaccination decreases the risk of death or progression at 3 years in patients with NSCLC or stage IV melanoma treated with ICIs, contrary to the conclusions of Grippin *et al.*[1] We propose that time-alignment problems, including immortal time, contribute to these discrepancies.

In the original study, the start of follow-up was not aligned to the date of treatment assignment.[3] In particular, the vaccinated group included patients who received vaccines within 100 days following baseline ICI injection. Thus, vaccinated patients were guaranteed to be event-free (immortal) up to the time they received the vaccine, leading to so-called immortal time bias.[6] The authors tried to address such bias by excluding events occurring in the first 100 days. Unfortunately, this additional analysis induces another form of time-related bias, because the new start of follow-up (100 days post ICI) occurs after treatment assignment.[3] This misalignment could not have occurred in a target trial where start of follow-up and treatment assignment coincide with the date of randomization.

Furthermore, the time of eligibility was not aligned in the vaccinated and unvaccinated groups in the NSCLC cohort: patients in the unvaccinated group were eligible at the date of first ICI treatment, whereas patients in the vaccinated group were recruited at the ICI treatment just before vaccination. This misalignment can lead to preferential selection of patients who survived longer in the vaccinated group, again resulting in bias. By contrast, in the target trial, patients were included at the first ICI treatment in both arms, by design.

Finally, the authors originally included patients from 2015, more than five years before the COVID-19 vaccines were first available (December 2020). Patients diagnosed before 2020 had a zero probability of being vaccinated. This leads to so-called positivity violations[7] and to

confounding bias,[8] as ICI indications changed between 2015 and 2022 to include less advanced disease.[9] This is a form of study time misalignment, with the eligibility criteria and inclusion time being set after the treatment is assigned. By contrast, in the emulated target trial, patients can certainly not be included before the vaccine was available.

Discussion

While addressing key problems of time alignment in the original study, our analysis also has limitations. It might be prone to residual unmeasured confounding bias, for example from time-varying confounders such as side effects of ICI treatment, which were not available. There could also be bias due to the misspecification of models used for the inverse probability of censoring weights. Furthermore, given the available data, we could not emulate a target trial for influenza or pneumonia vaccines, which could serve as a negative control exposure[10] as attempted by Grippin *et al.* in the original investigations.

Yet, our results do not suggest an effect of COVID-19 vaccine on survival outcomes during ICI treatment, contrary to the claims by Grippin et al. However, we cannot exclude that there is a beneficial effect of COVID-19 vaccines on cancer outcomes, perhaps of lower magnitude, that we cannot detect with the given dataset. We therefore encourage future studies to apply causal inference methods to larger datasets with detailed records of COVID-19 vaccination and ICI administration. This will further clarify the effect of COVID-19 mRNA vaccination among cancer patients treated with ICIs.

References

1. Grippin AJ, Marconi C, Copling S, et al: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 1–10, 2025

2. Hernán MA, Sterne JAC, Higgins JPT, et al: A Structural Description of Biases That Generate Immortal Time. Epidemiology 36:107–114, 2025

3. Hernán MA, Sauer BC, Hernández-Díaz S, et al: Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol 79:70–75, 2016

4. Cashin AG, Hansford HJ, Hernán MA, et al: Transparent reporting of observational studies emulating a target trial: the TARGET Statement [Internet], 2025[cited 2025 Nov 2] Available from: https://www.bmj.com/content/390/bmj-2025-087179

5. Maringe C, Benitez Majano S, Exarchakou A, et al: Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. International Journal of Epidemiology 49:1719–1729, 2020

6. Suissa S: Immortal Time Bias in Pharmacoepidemiology. American Journal of Epidemiology 167:492–499, 2008

7. Petersen ML, Porter KE, Gruber S, et al: Diagnosing and responding to violations in the positivity assumption. Stat Methods Med Res 21:31–54, 2012

8. Hernán MA, Robins JM: Causal Inference: What If Boca Raton: Chapman&Hall/CRC. 2020

9. Gougis P, Jochum F, Abbar B, et al: Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective. eClinicalMedicine 70:102536, 2024

10. Lipsitch M, Tchetgen ET, Cohen T: Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies. Epidemiology 21:383–388, 2010

Table 1: Specification and emulation of a target trial of COVID-19 vaccines during ICI treatment in patients with NSCLC or melanoma cancer from the data presented in Grippin *et al.*

Protocol	Target trial specification	Target trial emulation
Eligibility criteria	For NSCLC: patients diagnosed with stage III or stage IV NSCLC confirmed by biopsy after the COVID-19 vaccine were available and before September 2022, initiating ICI treatment. For melanoma: patients diagnosed with stage IV melanoma after the COVID-19 vaccines were available and before September 2022, initiating ICI treatment. Time zero is defined as the date of first ICI treatment.	Same as for the target trial. The COVID-19 vaccines were first available in December 2020. Therefore, we included patients initiating ICI in 2020, 2021, and 2022. We excluded patients who entered the original cohort after their first ICI initiation. We also excluded patients with missing ECOG data and assumed that ECOG missingness was completely at random.
Treatment strategies	(i) get a COVID-19 vaccine within 100 days of the first injection of ICI. The choice of vaccine and the date of the injection are left to the choice of the physician and patients. (ii) do not get a COVID-19 vaccine within 100 days of the first injection of ICI.	Same as for the target trial.*

Treatment assignment	Individuals are randomly assigned to a strategy at baseline, and individuals and their treating physicians will be aware of the assigned treatment strategy.	We cloned patients at baseline into two copies, one for each strategy, then artificially censored the clones if and when the behaviour of the patient was no longer consistent with the strategy assigned to the clone. Since the precise date of vaccination was not available in the data, we censored all vaccinated patients in the no vaccine arm at 100 days. We then re-weighted the clones using inverse probability of censoring (IPC) weights to adjust for baseline confounding covariates. IPC weights were set to 1 during the grace period (100 days) for all patients, and were then updated once, at the end of the grace period, for patients still at risk. The probability of remaining uncensored was estimated using a logistic regression model fitted on the confounding covariates. Confounding covariates were chosen based on expert knowledge and included socio-demographic variables and comorbid conditions.** Time-varying confounding covariates were not available in the data.
Outcomes	For NSCLC: overall survival (OS) For melanoma: overall survival and progression-free survival (PFS).	Same as in the target trial. OS and PFS were defined as done in the analysis of Grippin *et al*. (PFS was a composite outcome of progression and death)
Follow-up	Starts at baseline (ICI initiation) and ends in September 2024.	Same as in the target trial.
Causal contrasts	Per-protocol effect	Same as in the target trial.

Statistical analysis	Censor individuals if and when they deviate from their assigned treatment strategy and apply inverse-probability weights to adjust for baseline and time-varying confounding factors. No adjustment for administrative censoring, which is considered non-informative.	Same as in the target trial, except that adjustment is made for baseline confounding factors only, since time-varying confounding factors were not available in the data (see treatment assignment). We estimated weighted Kaplan-Meier survival curves and reported OS and PFS at 36 months (3 years). We used the non-parametric bootstrap with 1,000 iterations to estimate the 95% CIs based on percentiles. Patients included in 2022 had 24 months of maximum follow-up. Consequently, after 24 months of follow-up, the survival curves require extra assumptions about non-informative censoring to have a valid causal interpretation.*** Analyses were conducted with R version 4.5.0.

*It was unclear in the data if the patients without a COVID-19 vaccine were never vaccinated throughout follow-up or only within 100 days. **In the NSCLC cohort, the variables used for adjustment were: gender, ethnicity, age at ICI start (numeric), English as primary language, ECOG, heart disease, immune deficiency, diabetes, respiratory condition, chronic kidney disease (CKD), central nervous system (CNS) disease, and liver failure. In the melanoma cohort for overall survival, the variables used for adjustment were: gender, ethnicity, age at ICI start (numeric), English as primary language, ECOG, heart disease, immune deficiency, diabetes, respiratory condition, previous history of malignant at ICI start, and CKD. In the melanoma cohort for progression-free survival, the variables used for adjustment were: gender, age at ICI start (numeric), ECOG, heart disease, immune deficiency, diabetes, respiratory condition, previous history of malignant at ICI start, and CKD. The three adjustment sets differed slightly because we omitted variables leading to convergence issues due to small sample sizes in the logistic model used to estimate the weights. To avoid convergence issues in the model, the ethnicity variable was recorded as a binary variable: “caucasian” versus “non-caucasian”. One patient in the NSCLC cohort and two patients in the melanoma cohort had age

at ICI initiation coded as “>89”. We imputed age at 90 for these three patients. ***These assumptions will be discussed in detail in a future work (Gasparollo et al., forthcoming).

Figure 1: Study flowchart (A) for the NSCLC cohort and for (B) the stage IV melanoma cohort.



Figure 2: Adjusted Kaplan-Meier survival curves, risk tables, and estimates after 3 years for (i) NSCLC – overall survival, (ii) stage IV melanoma - overall survival, and (iii) stage IV melanoma – progression-free survival. In the risk tables, we present the numbers at risk after cloning but before weighting the patients. The vertical error bars at 12, 24 and 36 months represent confidence intervals around the curves at 1, 2 and 3 years, respectively. Abbreviations: OS: overall survival, PFS: progression-free survival, ICI: immune checkpoint inhibitors.



Data availability statement

The data used in this study are publicly available. The source code to reproduce the results is available on Github (https://github.com/elisedms/target-trial-emulation-covid-vaccine-ICI).

Ethical approval

Ethical approvals for the data used in this study were obtained by the investigators responsible for the original publication. We reanalyzed data that already are publicly available.

Funding

This study was funded by the Swiss National Foundation grant number 207436 (MJS and LG). The funding source had no role in the design of the study, interpretation of the data, or decision to submit results.

Contributor and guarantor information

JPS and MJS conceived the study. ED and LG performed the analyses.
ED, PG, and MJS wrote the first draft of the manuscript. All authors commented on the first draft of the manuscript and approved its final version. ED is the guarantor. The corresponding author attests that all listed authors meet the authorship criteria and that no others meeting the criteria have been omitted.

Transparency declaration

The manuscript guarantor (ED) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Copyright/license for publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in

all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Competing interests declaration

All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; PG has received research grant from Sanofi; JPS has received research grant from MSDAvenir; JPS reports consultant or advisory role fees from Roche, MSD, BMS, Lilly, AstraZeneca, Daiichi-Sankyo, Mylan, Novartis, Pfizer, PFO, LeoPharma, Incyte, and Gilead; MJS reports stock, honoraria, and consulting or advisory role from Novartis; no other relationships or activities that could appear to have influenced the submitted work.

Patient and Public Involvement
Not applicable